Skip to content

Study · Randomized controlled trial · n = 27 · 2016

6 results

Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.

Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association1 Feb 2016Cited by 47 (Europe PMC)

PMID26844873 (opens in a new tab)DOI10.1016/j.cgh.2015.12.049 (opens in a new tab)PepBankPUB-26844873
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In polycystic kidney and liver disease, TLV fell 130.2 ± 133.2 mL with octreotide versus a 144.3 ± 316.8 mL placebo increase after treatment.

    In plain wordsIn patients with polycystic kidney and liver disease, liver volume decreased with octreotide and increased with placebo after treatment.

    Peptide
    Octreotide
    Outcome
    DecreaseAbsolute TLV change after treatment
    Study

    n = 27

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Measurements

    TLV decrease
    130.2 mL
    octreotide
    SD
    133.2 mL
    octreotide
    TLV increase
    144.3 mL
    placebo
    SD
    316.8 mL
    placebo
    Between-group P
    0.004
    reported comparison
    Within-octreotide P
    0.003
    reported comparison

    Source sentences

    Summary
    After 3 years, TLV decreased by 130.2 ± 133.2 mL in patients given octreotide LAR (7.8% ± 7.4%) (P = .003) but increased by 144.3 ± 316.8 mL (6.1% ± 14.1%) in patients given placebo.
    4 context sentences
    Summary · context
    Change vs baseline differed significantly between groups (P = .004).
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In polycystic kidney and liver disease, TLV fell 7.8% ± 7.4% with octreotide versus a 6.1% ± 14.1% placebo increase after treatment.

    In plain wordsIn patients with polycystic kidney and liver disease, percentage liver-volume change favored octreotide over placebo after treatment.

    Peptide
    Octreotide
    Outcome
    DecreasePercentage TLV change after treatment
    Study

    n = 27

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Measurements

    TLV decrease
    7.8%
    octreotide
    SD
    7.4%
    octreotide
    TLV increase
    6.1%
    placebo
    SD
    14.1%
    placebo
    Between-group P
    0.004
    reported comparison

    Source sentences

    Summary
    After 3 years, TLV decreased by 130.2 ± 133.2 mL in patients given octreotide LAR (7.8% ± 7.4%) (P = .003) but increased by 144.3 ± 316.8 mL (6.1% ± 14.1%) in patients given placebo.
    4 context sentences
    Summary · context
    Change vs baseline differed significantly between groups (P = .004).
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In polycystic kidney and liver disease, TLV remained 14.4 ± 138.4 mL below baseline after octreotide versus 224.4 ± 331.7 mL above after placebo.

    In plain wordsIn patients with polycystic kidney and liver disease, liver volume remained lower after octreotide than placebo, two years after treatment.

    Peptide
    Octreotide
    Outcome
    DecreaseAbsolute TLV change 2 years after treatment
    Study

    n = 27

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Measurements

    TLV decrease
    14.4 mL
    octreotide
    SD
    138.4 mL
    octreotide
    TLV increase
    224.4 mL
    placebo
    SD
    331.7 mL
    placebo
    Between-group P
    0.046
    reported comparison

    Source sentences

    Summary
    Two years after treatment ended, TLV had decreased 14.4 ± 138.4 mL (0.8% ± 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 ± 331.7 mL (11.0% ± 14.4%) in patients given placebo.
    4 context sentences
    Summary · context
    Changes vs baseline still differed significantly between groups (P = .046).
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In polycystic kidney and liver disease, TLV remained 0.8% ± 9.7% below baseline after octreotide versus 11.0% ± 14.4% above after placebo.

    In plain wordsIn patients with polycystic kidney and liver disease, percentage liver-volume change favored octreotide over placebo two years after treatment.

    Peptide
    Octreotide
    Outcome
    DecreasePercentage TLV change 2 years after treatment
    Study

    n = 27

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Measurements

    TLV decrease
    0.8%
    octreotide
    SD
    9.7%
    octreotide
    TLV increase
    11%
    placebo
    SD
    14.4%
    placebo
    Between-group P
    0.046
    reported comparison

    Source sentences

    Summary
    Two years after treatment ended, TLV had decreased 14.4 ± 138.4 mL (0.8% ± 9.7%) from baseline in patients given octreotide LAR but increased by 224.4 ± 331.7 mL (11.0% ± 14.4%) in patients given placebo.
    4 context sentences
    Summary · context
    Changes vs baseline still differed significantly between groups (P = .046).
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with polycystic kidney and liver disease, no patient withdrew because of side effects, including those receiving octreotide.

    In plain wordsIn patients with polycystic kidney and liver disease, no patient, including octreotide recipients, withdrew because of side effects.

    Peptide
    Octreotide
    Outcome
    Not applicableWithdrawal due to side effects
    Study

    n = 27

    Outcome group
    Adverse events · Whole body
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    No patient withdrew because of side effects.
    3 context sentences
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.
  6. 06HumanObservational studyEfficacy outcome

    In patients with polycystic kidney and liver disease given octreotide, liver-volume decreases were similar in each sex.

    In plain wordsIn patients with polycystic kidney and liver disease given octreotide, liver-volume decreases were similar in each sex.

    Peptide
    Octreotide
    Outcome
    Direction not reportedLiver-volume decrease by sex
    Study

    n: not reported in source

    Comparator
    the other sex
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg monthly · 3 yearsAs given in this study (human).

    Source sentences

    Summary
    Decreases in TLV were similar in each sex; the change in TLV was greatest among subjects with larger baseline TLV.
    3 context sentences
    Summary · context
    We performed a controlled study of adults with polycystic kidney and liver disease (estimated glomerular filtration rate, 40 mL/min/1.73m(2) or more) at a single center in Italy.
    Summary · context
    We analyzed data from 27 patients randomly assigned to groups given octreotide LAR (40 mg, n = 14) or placebo (n = 13) each month for 3 years.
    Summary · context
    The primary outcome was absolute and percentage change in total liver volume (TLV), which was measured by magnetic resonance imaging at baseline, after 3 years of treatment, and then 2 years after treatment ended.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.